[extropy-chat] Drug discovery software

[ARTILLO at comcast.net]

I thought this was interesting enough to pass on....
- Arti

news release from Laboratorytalk.com
____________________________________________________________
SOFTWARE 'WILL IRREVOCABLY CHANGE' DRUG DISCOVERY
____________________________________________________________
Date: 28 October 2005
News from: Quantum Pharmaceuticals
Product: Quantum 3.1
http://www.laboratorytalk.com/news/qan/qan104.html
Quantum Pharmaceuticals is issuing its first commercial release of research software that it says is expected to speed up pharma R and D radically and irrevocably change the drug discovery software market. Quantum 3.1 is a suite of drug discovery
software for Linux and Windows designed to enhance stages of drug discovery workflows, such as target identification, drug hit identification, lead identification and lead optimisation. The Quantum software was developed using a new paradigm in molecular
modelling - applying quantum and molecular physics instead of statistical scoring-function-like and Qsar-like methods. The key benefit of Quantum is the outstanding precision of molecular modeling and calculations, says the company. Using Quantum 3.1,
researchers can calculate the IC50 of protein-ligand and protein-protein complexes, perform ligand docking, perform virtual screening of small-molecule libraries, analyse large-scale protein movements, perform de novo drug design and calculate the
solvation energy and solubility. Quantum 3.1 also helps detect potential moderate-to-serious adverse activity, additional unexpected activity and broad relative selectivity for a library of compounds by screening them against several hundred
Adme/Tox-associated proteins. The Mutagenesis module of Quantum 3.1 provides an interface for changing the protein sequence at specific sites through alterations to its amino acids and predicts changes in the bioactivity after mutations. The Quantum
software was successfully applied in different in-house and collaborative drug discovery projects of Quantum Pharmaceuticals. As a result of applying Quantum software, the range of the novel chemical inhibitor classes were discovered for disease targets,
including HIV-I integrase (Aids), Beta-Secretase (Alzheimer's disease), Human Neutrophil Elastase (CF, COPD), FtsZ (TB) and some others. Quantum technology has demonstrated itself to be very effective in creating revolutionary new medicine, and it has
demonstrated its ability to discover new classes of inhibitors, says the company. The free demo version of Quantum 3.1 can be downloaded from Quantum's website. Quantum Pharmaceuticals says it serves the life sciences industry and research community by
providing top-of-the-line drug discovery products and services. Since 2002 Quantum Pharmaceuticals has been developing its proprietary computer-based molecular modelling technology. It says the Quantum technology includes the latest achievements in the
fields of physics, mathematics and chemistry. It demonstrates outstanding speed and accuracy of affinity calculations using fast quantum calculations which take into account the full flexibility of molecules, solvation effects and entropy contribution.
This provides unprecedented possibilities for drug discovery. The headquarters of Quantum Pharmaceuticals is in Moscow, and its worldwide distribution network is expanding.
For a brochure or catalogue on this product, please email
mailto:courtney.ranson at q-pharm.com
(Please mention Laboratorytalk when requesting more
information from Quantum Pharmaceuticals)
Quantum Pharmaceuticals
Moscow, Russia
Telephone: (Russia) +7 095 152 9615
Fax: (Russia) +7 095 152 1739
Website: http://www.q-pharm.com
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.extropy.org/pipermail/extropy-chat/attachments/20051102/845fde57/attachment.html>